INVA
Innoviva Inc
NASDAQ: INVA · HEALTHCARE · BIOTECHNOLOGY
$22.99
-0.26% today
Updated 2026-04-30
Market cap
$1.71B
P/E ratio
6.98
P/S ratio
4.15x
EPS (TTM)
$3.30
Dividend yield
—
52W range
$17 – $25
Volume
0.7M
Innoviva Inc (INVA) Financial statements
SEC filings — annual and quarterly data.
Profit margin
65.90%
Operating margin
34.70%
ROE
29.10%
ROA
7.18%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $19.59M | $-166.04M | 100.00% | -914.74% | -847.73% |
| 2007 | $22.00M | $-160.00M | 100.00% | -766.13% | -727.19% |
| 2008 | $23.10M | $-93.64M | 100.00% | -380.09% | -405.45% |
| 2009 | $24.37M | $-85.30M | 100.00% | -329.10% | -349.97% |
| 2010 | $24.22M | $-83.86M | 100.00% | -323.34% | -346.21% |
| 2011 | $24.51M | $-115.34M | 100.00% | -447.69% | -470.56% |
| 2012 | $5.61M | $-18.54M | -45.25% | -231.59% | -330.34% |
| 2013 | $4.53M | $-170.70M | -99.43% | -635.37% | -3,766.57% |
| 2014 | $8.43M | $-168.46M | 11.09% | -402.34% | -1,997.68% |
| 2015 | $53.95M | $-18.76M | 95.15% | 58.54% | -34.77% |
| 2016 | $133.57M | $59.54M | 98.96% | 81.60% | 44.57% |
| 2017 | $217.22M | $134.14M | 100.00% | 84.53% | 61.76% |
| 2018 | $261.00M | $395.06M | 100.00% | 91.28% | 151.36% |
| 2019 | $261.02M | $157.29M | 100.00% | 94.39% | 60.26% |
| 2020 | $336.79M | $224.40M | 0.10% | 95.35% | 66.63% |
| 2021 | $391.87M | $265.85M | 100.00% | 95.72% | 67.84% |
| 2022 | $331.34M | $213.92M | 95.84% | 62.47% | 64.56% |
| 2023 | $310.46M | $179.72M | 86.27% | 36.68% | 57.89% |
| 2024 | $358.71M | $23.39M | 89.80% | 46.52% | 6.52% |
| 2025 | $425.13M | $271.17M | 72.33% | 38.52% | 63.78% |